Eli Lilly's Donanemab Faces EU Setback Despite 16.86 Billion Trading Volume Ranking 26th

On March 28, 2025, Eli Lilly (LLY) saw a trading volume of 16.86 billion, ranking 26th in the day's stock market activity. The stock price increased by 0.10%.

Eli Lilly's Alzheimer's drug, donanemab, faced a significant setback as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion. This decision was based on concerns over the drug's limited impact on patients and potential risks of serious side effects, including brain bleeding. Analysts anticipate that Eli Lilly may appeal this decision, citing past instances where similar negative opinions were reversed.

In response to the regulatory challenges, Eli Lilly has expanded its LillyDirect platform to include Alzheimer's disease treatments. This move underscores the company's commitment to providing patients with access to the care they need, when they need it. The platform aims to empower patients by helping them locate appropriate treatment options.